Table 2.
Predictors of liver injury hospitalization among patients with atrial fibrillation initiating oral anticoagulation in the derivation and validation samples, MarketScan 2011–2014. Results correspond to a Cox model including all the variables in the table simultaneously.
| Derivation sample | Validation sample | |
|---|---|---|
| Liver injury hospitalizations / total | 638 / 75,851 | 322 / 37,866 |
| Hazard ratios (95% confidence intervals) | ||
| Liver disease | 2.49 (1.98, 3.14) | 2.73 (1.99, 3.74) |
| Gallbladder disease | 2.23 (1.64, 3.03) | 1.90 (1.21, 2.98) |
| Alcoholism | 2.21 (1.55, 3.14) | 2.31 (1.42, 3.76) |
| Kidney disease | 1.64 (1.34, 2.00) | 1.34 (1.00, 1.78) |
| Cancer | 1.45 (1.20, 1.76) | 1.46 (1.11, 1.92) |
| Anemia | 1.40 (1.17, 1.67) | 1.58 (1.23, 2.02) |
| Heart failure | 1.28 (1.08, 1.52) | 1.36 (1.08, 1.72) |
| DOAC (vs warfarin) | ||
| Dabigatran | 0.57 (0.44, 0.73) | 0.47 (0.31, 0.69) |
| Rivaroxaban | 0.84 (0.69, 1.02) | 0.78 (0.59, 1.02) |
| Apixaban | 0.74 (0.50, 1.08) | 0.49 (0.26, 0.93) |
| C-statistic* | 0.669 (0.642, 0.696) | 0.690 (0.655, 0.726) |
| Calibration [χ2, (p-value)]* | 6.1 (p = 0.73) | 14.1 (p = 0.12) |
*
12-month time horizon